Vesting condition for the incentive have been met. A well deserved reward for the Neuren employees if you ask me
from the annoucment dated 03/02/2022
Material terms:- Exercise price ($3.46 per share) is the volume weighted average price (VWAP) at which the Company's shares weretraded on the ASX in the 5 days preceding the date of issue of the Options.
- Vested options may be exercised no earlier than 1 year after the issue date.
- All options lapse 4 years after the issue date.
- Options are subject to the following vesting conditions:
(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a MarketingAuthorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.- The options carry no entitlement to vote or participate in new issues.
- Forums
- ASX - By Stock
- NEU
- Ann: Application for quotation of securities - NEU
Ann: Application for quotation of securities - NEU, page-9
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.80 |
Change
-0.120(0.86%) |
Mkt cap ! $1.744B |
Open | High | Low | Value | Volume |
$13.94 | $13.96 | $13.50 | $2.987M | 218.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 207 | $13.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.81 | 598 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 89 | 13.790 |
8 | 533 | 13.780 |
6 | 364 | 13.770 |
8 | 811 | 13.760 |
6 | 1838 | 13.750 |
Price($) | Vol. | No. |
---|---|---|
13.800 | 505 | 16 |
13.810 | 631 | 9 |
13.820 | 859 | 11 |
13.830 | 742 | 13 |
13.840 | 868 | 7 |
Last trade - 13.25pm 06/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |